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Introduction: Folfox-4 is the standard adjuvant treatment in stage III colon cancer and is
also recommended in high-risk stage II colon cancer. Oxaliplatin-based regimens are con-
sidered moderately emetogenic therapies. Palonosetron, a new selective inhibitor of 5-HT3
receptors, in combination with dexhametasone showed a high antiemetic activity in piv-
otal trials enrolling patients treated with moderately or high emetogenic regimens. Consid-
ering these data, the GOIM started a multicentre phase II trial aiming to evaluate the
activity and safety of palonosetron plus dexhametasone in patients affected by radically
resected colorectal cancer and treated with adjuvant folfox-4.
Materials and methods: Patients with stage III or high-risk stage II colorectal cancer and
receiving folfox-4 as adjuvant treatment entered into the trial. Informed written consent
was required. A single pretreatment dose of palonosetron 0.25 mg (intravenous) i.v. fol-
lowed by dexamethasone 8 mg i.v. was administered. Nausea and vomiting were evaluated
on day 1 and over the following 4 d, with a patient diary including vomiting episodes, daily
nausea and use of rescue medications. The main end-point of the study was the absence of
vomiting in the entire period (5 d) at the first cycle. The absence of moderately or severe
nausea and vomiting on days 1–5 was the secondary end-point. Adverse events were eval-
uated according to the NCI-CTC criteria.
Results: Eighty-five patients entered into the study and were all evaluable for activity and
safety. The absence of vomiting on the study period (days 1–5) was observed in 82
(96.5%) patients: one patient on the 1st and two on the 2nd day experienced mild vomiting.
With respect to the secondary end-point, the complete control during the acute phase was
96.5% while during the late phase was 92%. The complete responses during the acute and
delayed phases were 99% and 89.5%, respectively. The main side-effects (G1 grade) were:
constipation 13%, headache 10%, vertigo and insomnia 2%.
Conclusions: Palonosetron is a very active antiemetic drug for the prevention of nausea and
vomiting induced by folfox-4 regimen.
 2008 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved.
; fax: +39 080 5555232.
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15,16Chemotherapy-induced nausea and vomiting (CINV) repre-
sents one of the most distressing experiences of cancer treat-
ment. CINV significantly impairs quality of life, interferes
with daily functions, can cause medical complications such
as dehydration, malnutrition or electrolyte imbalance, and
may affect the patients’ ability to continue with the scheduled
chemotherapy influencing survival in this way.1
Two major phases of CINV have been identified: an acute
phase beginning immediately after the chemotherapy admin-
istration and resolving within 24 h and a delayed phase start-
ing 24 or more hours after chemotherapy and lasting up to
120 h, rarely more, depending on the employed regimens.2 A
third category is anticipatory CINV that typically responds
better to behavioural modification or non-pharmacological
approach.3 The control of both acute and delayed CINV is a
relevant objective for the patient’s quality of life and also aims
to optimise cancer treatment.
The introduction of 5-HT3 receptor antagonists, ondanse-
tron, granisetron, tropisetron and dolasetron, has deter-
mined a better control of emesis when compared with the
traditional metoclopramide, and the addition of a corticoste-
roid to these 5-HT3 receptor antagonists, further improves
the control of CINV with a response rate during the acute
phase ranging from 50% to 70%.4,5 In contrast, the effective-
ness of the 5-HT3 receptor antagonists in preventing delayed
CINV is less well established with some experiences report-
ing about 50% of the control.6,7 The toxicity profile of 5-
HT3 receptor antagonists is modest, the main side-effects
being headache and constipation in 10–15% of patients. De-
spite some pharmacological differences, all these 5-HT3
receptor antagonists are considered therapeutically equiva-
lent and interchangeable when employed at equipotent
doses.8–10
Nevertheless, 5-HT3 receptor antagonists have increased
the control of CINV, a substantial proportion of patients con-
tinue to experience both acute and particularly delayed CINV
after moderately and high emetogenic chemotherapy. There-
fore, there is a strong need to develop new agents to improve
control rate and patient care.
Palonosetron is a highly potent second generation selec-
tive 5-HT3 receptor antagonist with a 100-fold stronger bind-
ing affinity for the 5-HT3 receptor.11 In contrast to other 5-HT3
receptor antagonists that exist as racemic mixtures, Palo-
nosetron exists as a single stereoisomer with better pharma-
cological and pharmacokinetic profiles.12 In preclinical
studies, palonosetron demonstrated potent antiemetic prop-
erties in several animal models, and in previous phase I stud-
ies Palonosetron was found to be well tolerated and to have
mean plasma elimination half-life values of about 40 h,13
longer than that of ondansetron (4–6 h), granisetron (5–8 h),
tropisetron (7 h) and dolasetron (7 h).14 Both the high binding
affinity and the long half-life give palonosetron the possibility
to provide more complete and prolonged protection against
CINV than that of the other 5-HT3 receptor antagonists. In
two randomised studies, a single intravenous dose of Palo-
nosetron 0.25 mg provided a statistically significant improve-
ment in complete response compared with ondansetronately emetogenic chemotherapy. In both these studies,
corticosteroids were not added to 5-HT3 receptor antagonist
premedication. In another randomised trial enrolling patients
treated with highly emetogenic chemotherapy, Palonosetron
plus dexhametasone proved to be at least as effective as
ondansetron in preventing acute CINV with a slightly higher
control of delayed CINV.17
Oxaliplatin (L-OHP) plus 5-fluorouracil (5FU) modulated by
folinic acid (FA) and administered part in bolus and part in
continuous infusion according to the De Gramont’s schedule
is considered the standard adjuvant treatment in stage III
and is recommended in stage II high-risk colorectal cancer
(CRC) patients.18 Oxaliplatin is considered a moderately eme-
togenic drug19–21 and the current guidelines recommend to
employ a combination of 5-HT3 receptor antagonist plus dex-
hametasone as prophylactic antiemetic regimen in patients
treated with moderately emetogenic chemotherapy.22
Considering these data, the GOIM started a multicentre
phase II study to evaluate the activity and safety of Palo-
nosetron plus dexhametasone in preventing acute and de-
layed CINV in adjuvant CRC patients treated with folfox-4
regimen.
2. Patients and methods
2.1. Patients selection
Eligible patients were chemonaive males or females P18
years of agewith histological diagnosis of stage III or high-risk
stage II colorectal cancer and were candidates to receive fol-
fox-4 regimen as adjuvant treatment. Patients had to have a
performance status 0–1 (ECOG scale), adequate bone marrow
reserve and renal and hepatic function and no cardiovascular
impairments. Patients had to be available to complete their
diary and to sign written informed consent; fertile women
had to use an adequate contraception.
Patients were excluded if they were unable to understand
or cooperate with the study procedures and if they had taken
any antiemetic drug within 24 h prior to treatment until day
5 post-treatment. Evidence of disorders requiring anticonvul-
sant therapy, clinical evidence of intestinal subocclusion,
electrolytes abnormalities, presence of nausea or vomiting
during the screening phase were considered exclusion
criteria.
2.2. Study design and treatment regimen
This was a multicentre phase II study conducted in four Ital-
ian centres. The study protocol was approved by the Ethic
Committee of each participating site.
The enrolled patients received a single dose of Palonose-
tron 0.25 mg i.v. bolus plus dexhametasone 8 mg i.v. on day
1, 30 minutes before the folfox-4 regimen that was adminis-
tered as follows: oxaliplatin at 85 mg/m2 on day 1, folinic acid
at 100 mg/m2 on days 1–2, fluorouracil bolus at 400 mg/m2 on
days 1–2 and fluorouracil 22 h continuous infusion on days 1–
2, every 2 weeks.
Only dexhametasone was permitted as rescue medication.
Table 1 – Patients’ characteristics
Median age 67 years (range = 27–82 years)
Sex M: 56 points (66%)
F: 29 points (34%)
PS (ECOG) 0: 68 points (80%)
1: 17 points (20%)
Primary site of disease Colon: 61 points (72%)
Rectum: 24 points (28%)
Stage IIB: 25 points (30%)
III: 60 points (70%)
Table 2 – Primary end-point: complete response
Absent Present
Vomiting (days 1–5) 82 (96%) 3 (4%)
Table 3 – Secondary-end-point: complete control
Number of patients (%)
Day 1 82 (96.5%)
Days 2–5 79 (92%)
Table 4 – Secondary-end-point: complete response and
number of nausea and vomiting episodes
Absent Mild Moderate Severe
Nausea (day 1) 72 (85%) 11 (13%) 2 (2%) 0
Nausea (days 2–5) 68 (80%) 13 (15%) 3 (4%) 1 (1%)
Vomiting (day 1) 84 (99%) 1* (1%) 0 0
Vomiting
(days 2–5)
83 (97%) 2** (3%) 0 0
* Acute phase.
** Delayed phase.
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The primary efficacy end-point of the study was the overall
percentage of patients who achieved a complete response de-
fined as no episodes of vomiting without use of rescue medi-
cation for the entire period of study (0–120 h).
The secondary end-points assessed during the acute
phase (within the first 24 h after chemotherapy) and during
the late phase (24–120 h) separately for each day and for the
entire period, included: full control percentage (defined as
no episodes of vomiting, without use of rescue medication,
with maximum degree of nausea = mild), complete response
during acute phase, nausea intensity classified according to
Likert’s scale (from zero = none to 3 = severe), number and
duration of episodes of vomiting, the global satisfaction of
the antiemetic therapy, measuredwith a visual-analogic scale
(VAS), and the safety.
2.4. Study visits and procedures
Consenting patients were initially screened for 15 d before
starting treatment. During this time period the following were
recorded: history of nausea and vomiting, physical examina-
tion, vital signs, weight and performance status, laboratory
tests, concomitant medications.
During the first 24 h after the treatment (day 1) each pa-
tient reported on his diary the following: number and timing
of emetic episodes, use of rescue medication, severity of nau-
sea and patient global satisfaction.
On days 2–5, each patient reported on his diary the follow-
ing: emetic episodes, severity of nausea, rescue medication,
other side-effects.
Safety was evaluated for a period of 15 d, according to NCI
common toxicity criteria NCTC version 2.
2.5. Statistical analysis
The statistical analysis was performed according to Fleming’s
one step study design.23 Considering p = 0.20 as null hypothe-
sis and pP 0.35 as acceptable hypothesis, with an a er-
ror = 0.05 and b = 0.90, at least 77 patients had to be
enrolled. Adding about 5% of patients not eligible, or lost to
follow-up or withdrew for major violation, a minimum of 81
patients had to be enrolled.
The evaluation of the primary and secondary end-points
was performed according to an intent-to-treat (ITT) analysis.
3. Results
FromOctober 2006 to November 2007, 85 patients entered into
the study. Their main characteristics were median age: 67
years (range 27–82), median PS: 0 (range 0–1), primary site: co-
lon 61 (72%) and rectum 24 (28%), stage III: 60 (70%), high-risk
stage II: 25 (30%) (Table 1).
All patients were evaluable for activity and safety. With re-
gard to the primary end-point, the number of patients who
achieved a complete response (absence of vomiting during
the overall treatment period of the study 0–120 h) was 82
(96.5%) (Table 2). With regard to the secondary end-points,
the complete control during the acute phase was 96.5%, whileduring the delayed phase was 92% (Table 3). The complete re-
sponses during the acute and late phases were 99% and
89.5%, respectively (Table 4).
The treatment was well tolerated. Consistent with previ-
ous studies with 5-HT3 receptor antagonists, we observed
the following percentage of toxicities: headache 10%, consti-
pation 13%, vertigo 2%, insomnia 2%. All the toxicities were
mild in severity. There were no significant treatment-related
changes in laboratory measures or vital signs. Themedian va-
lue of patients’ satisfaction was very high with 9 points (range
2–10).
4. Discussion
At our knowledge this study is the largest phase II trial evalu-
ating the role of single dose Palonosetron plus dexhameta-
sone in preventing acute and delayed CINV in a
homogeneous chemonaive cancer patient population. With
regard to the primary end-point, i.e. the number of patients
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study period), the rate was 96.5%. In the acute phase, the per-
centage of complete control (absence of vomiting with maxi-
mum mild nausea) was 96.5%, while in the late phase the
complete control was observed in 92% of patients. The com-
plete responses during the acute and late phases were 99%
and 89.5%, respectively. These results are the best reported
in the literature. No patients delayed the treatment due to
emesis and this result, considering the importance to main-
tain a correct timing of chemotherapy administration in an
adjuvant setting, seems also more relevant to us.
The Palonosetron dose used in this study was based on a
phase II dose-ranging study showing Palonosetron 3.0 lg/kg
(fixed dose of approximately 0.25 mg) to be the minimally
effective dose for the prevention of highly emetogenic CINV.24
The addition of dexhametasone at 8 mg was based according
to the current guidelines for preventing CINV in patients trea-
ted with moderately emetogenic chemotherapies. We chose
to treat a homogeneous population, regarding the type of can-
cer and the chemotherapy regimen administered, to evaluate
the real impact of Palonosetron in preventing acute and de-
layed CINV. The pivotal phase III trials exploring the activity
of Palonosetron did not use the 5-HT3 receptor antagonist in
combination with dexhametasone and enrolled heteroge-
neous populations of patients with the disadvantage to have
no uniform elegibility criteria and to employ different chemo-
therapy regimens.15,16 These reasons could explain the better
results observed in our experience compared to the others. In
another little phase II trial Palonosetron 0.25 mg was admin-
istered in combination with dexhametasone at 8 mg, as in
our study, to 32 patients receiving at least one qualifying
moderately emetogenic agents such as cyclophosphamide,
doxorubicin, carboplatin or oxaliplatin. Twenty-seven (84%)
patients had a complete response during the acute phase
and 19 (59%) had a complete response during the delayed
interval.25 Also these results are slightly inferior to those ob-
served in our experience and maybe reflect the difference in
the chemotherapeutic regimens employed.
Palonosetron was well tolerated. Only a small proportion
of events were considered possibly or probably related to
study medication. Consistent with previous studies of 5-HT3
receptor antagonists the most frequently reported adverse
events were mild headache 10%, constipation 13%, vertigo
and insomnia 2%, respectively.
The antiemetic treatment was appreciated by the study
population with a median value of patients’ satisfaction, mea-
sured by VAS scale, of 9 points (range 2–10).
In conclusion Palonosetron plus dexhametasone given as
pretreatment infusion is effective and safe in preventing
acute and delayed CINV in CRC patients receiving moderately
emetogenic folfox-4 regimen. This combination is recom-
mended as the most active to prevent acute and delayed CINV
in CRC adjuvant setting.Conflict of interest statement
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